Cholesterol-Lowering Interventions and Stroke. Insights From a Meta-Analysis of Randomized Controlled Trials

Journal of the American College of Cardiology

Volumn 55, Issue 3, 2010, Pages 198-211

  De Caterina, Raffaele ^a,b   Scarano, Marco ^c   Marfisi, RosaMaria ^c   Lucisano, Giuseppe ^c   Palma, Francesco ^a   Tatasciore, Alfonso ^a   Marchioli, Roberto ^c  

^a UNIVERSITY OF CHIETI   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c Santa Maria Imbaro   (Italy)

Author keywords

cholesterol; HMG CoA reductase inhibition; neuroprotection; pleiotropic effects; statins; stroke

Indexed keywords

FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TRIGLYCERIDES;

EID: 73849115520     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.062     Document Type: Article

References (36)

1. Martin M.J., Hulley S.B., Browner W.S., Kuller L.H., and Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 2 (1986) 933-936
2. Anderson K.M., Castelli W.P., and Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 257 (1987) 2176-2180
3. Tell G.S., Crouse J.R., and Furberg C.D. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review. Stroke 19 (1988) 423-430
4. Oliver M.F. Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ 320 (2000) 459-460
5. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
6. Manninen V., Elo M.O., Frick M.H., et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
7. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323 (1990) 946-955
8. Ornish D., Brown S.E., Scherwitz L.W., et al. Can lifestyle changes reverse coronary heart disease?. The Lifestyle Heart Trial. Lancet 336 (1990) 129-133
9. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
10. Byington R.P., Jukema J.W., Salonen J.T., et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92 (1995) 2419-2425
11. The West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 348 (1996) 1339-1342
12. de Faire U., Ericsson C.G., Grip L., Nilsson J., Svane B., and Hamsten A. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Eur Heart J 17 Suppl F (1996) 37-42
13. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
14. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
15. Andrews T.C., Raby K., Barry J., et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 95 (1997) 324-328
16. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
17. Plehn J.F., Davis B.R., Sacks F.M., et al., CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. Circulation 99 (1999) 216-223
18. White H.D., Simes R.J., Anderson N.E., et al. Pravastatin therapy and the risk of stroke. N Engl J Med 343 (2000) 317-326
19. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
20. Petitti D.B. Meta-Analysis: Decision Analysis and Cost-Effectiveness Analysis (1994), Oxford University Press, Oxford, UK
21. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., and Song F. Methods for Meta-Analysis in Medical Research (2000), Wiley & Sons, New York, NY
22. Berlin J.A., Laird N.M., Sacks H.S., and Chalmers T.C. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8 (1989) 141-151
23. Thompson S.G., and Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat Med 21 (2002) 1559-1573
24. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9 (1987) 1-30
25. Iso H., Jacobs Jr. D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
26. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 352 (1998) 1801-1807
27. Geluk C.A., Asselbergs F.W., Hillege H.L., et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 26 (2005) 1314-1320
28. Lewington S., Whitlock G., Clarke R., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
29. Amarenco P., and Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8 (2009) 453-463
30. Yano K., Reed D.M., and MacLean C.J. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20 (1989) 1460-1465
31. Anderson C.S., Chakera T.M., Stewart-Wynne E.G., and Jamrozik K.D. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry 57 (1994) 936-940
32. Broderick J., Connolly S., Feldmann E., et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update. A guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 38 (2007) 2001-2023
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
34. Emberson J.R., Ng L.L., Armitage J., Bowman L., Parish S., and Collins R. N-terminal pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49 (2007) 311-319
35. Amarenco P., Bogousslavsky J., Callahan A., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
36. Waters D.D., Schwartz G.G., Olsson A.G., et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695